Urothelial Cancer Clinical Trials

13 recruiting

Urothelial Cancer Trials at a Glance

25 actively recruiting trials for urothelial cancer are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Nashville, and Houston. Lead sponsors running urothelial cancer studies include National Cancer Institute (NCI), BicycleTx Limited, and Avenzo Therapeutics, Inc..

Browse urothelial cancer trials by phase

Treatments under study

About Urothelial Cancer Clinical Trials

Looking for clinical trials for Urothelial Cancer? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urothelial Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urothelial Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1Phase 2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Urothelial CarcinomaUrothelial CancerAdvanced/Metastatic Urothelial Cancer
Pfizer132 enrolled40 locationsNCT07421700
Recruiting
Phase 1Phase 2

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Urothelial CancerLocally AdvancedSolid Tumor Cancer+1 more
Avenzo Therapeutics, Inc.355 enrolled9 locationsNCT07193511
Recruiting
Phase 2Phase 3

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Urothelial Cancer
Bristol-Myers Squibb470 enrolled160 locationsNCT07106762
Recruiting

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Urothelial Cancer
Astellas Pharma Korea, Inc.202 enrolled18 locationsNCT06011954
Recruiting
Phase 1

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Metastatic Urothelial CarcinomaAdvanced Urothelial Cancer
Generate Biomedicines37 enrolled2 locationsNCT07484022
Recruiting

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

Urothelial CancerBladder CancerHealthy Volunteers+1 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02379429
Recruiting
Not Applicable

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Risk of Breast CancerRisk of Gynaecological CancerRisk of Colorectal Cancer+14 more
Gustave Roussy, Cancer Campus, Grand Paris5,909 enrolled1 locationNCT06907095
Recruiting
Phase 2Phase 3

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer
BicycleTx Limited956 enrolled170 locationsNCT06225596
Recruiting
Phase 2Phase 3

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial CancerBladder Cancer
Daiichi Sankyo630 enrolled79 locationsNCT07129993
Recruiting
Phase 2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Metastatic Urothelial Cancer
Gilead Sciences827 enrolled135 locationsNCT03547973
Recruiting

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

Urothelial Cancer
Comprehensive Cancer Center Munich (CCCM)80 enrolled4 locationsNCT06657157
Recruiting

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)1,100 enrolled1 locationNCT04923178
Recruiting
Phase 1

SLV-154 Treatment of Metastatic Solid Tumors

Breast Cancer MetastaticOvarian CancerEndometrial Cancer+7 more
Solve Therapeutics70 enrolled9 locationsNCT06771219
Recruiting

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

CancerUrothelial CancerUrinary Bladder Cancer+1 more
Lahey Clinic500 enrolled1 locationNCT00872495
Recruiting
Phase 2

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER400 enrolled1 locationNCT07259226
Recruiting
Not Applicable

Urine Methylation Markers in UTUC

Upper Tract Urothelial Cancer
Duke University50 enrolled1 locationNCT06805630
Recruiting
Phase 1Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Metastatic Urothelial CarcinomaUrothelial CancerBladder Cancer+1 more
Dana-Farber Cancer Institute106 enrolled1 locationNCT04724018
Recruiting
Phase 3

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Urothelial Cancer of Renal PelvisUrothelial Carcinoma Ureter
University of Texas Southwestern Medical Center132 enrolled1 locationNCT04865939